These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 19059209

  • 1. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK.
    Biochem Biophys Res Commun; 2009 Jan 16; 378(3):645-9. PubMed ID: 19059209
    [Abstract] [Full Text] [Related]

  • 2. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X, Li Z, Yang Z, Zheng C, Jing J, Chen Y, Ye X, Lian X, Qiu W, Yang F, Tang J, Xiao J, Liu M, Luo J.
    J Bone Miner Res; 2012 Jun 16; 27(6):1298-1308. PubMed ID: 22337253
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.
    J Bone Miner Res; 2011 Mar 16; 26(3):644-56. PubMed ID: 20814972
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor regulates osteoclast differentiation and survival through cross-talking with RANK signaling.
    Yi T, Lee HL, Cha JH, Ko SI, Kim HJ, Shin HI, Woo KM, Ryoo HM, Kim GS, Baek JH.
    J Cell Physiol; 2008 Nov 16; 217(2):409-22. PubMed ID: 18543257
    [Abstract] [Full Text] [Related]

  • 6. Paeonol inhibits RANKL-induced osteoclastogenesis by inhibiting ERK, p38 and NF-kappaB pathway.
    Tsai HY, Lin HY, Fong YC, Wu JB, Chen YF, Tsuzuki M, Tang CH.
    Eur J Pharmacol; 2008 Jun 24; 588(1):124-33. PubMed ID: 18495114
    [Abstract] [Full Text] [Related]

  • 7. JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts.
    Ikeda F, Matsubara T, Tsurukai T, Hata K, Nishimura R, Yoneda T.
    J Bone Miner Res; 2008 Jun 24; 23(6):907-14. PubMed ID: 18251700
    [Abstract] [Full Text] [Related]

  • 8. Possible involvement of protein kinases and Smad2 signaling pathways on osteoclast differentiation enhanced by activin A.
    Murase Y, Okahashi N, Koseki T, Itoh K, Udagawa N, Hashimoto O, Sugino H, Noguchi T, Nishihara T.
    J Cell Physiol; 2001 Aug 24; 188(2):236-42. PubMed ID: 11424090
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of osteoclast differentiation and bone resorption by sauchinone.
    Han KY, Yang D, Chang EJ, Lee Y, Huang H, Sung SH, Lee ZH, Kim YC, Kim HH.
    Biochem Pharmacol; 2007 Sep 15; 74(6):911-23. PubMed ID: 17662251
    [Abstract] [Full Text] [Related]

  • 13. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M, Otsuka F, Mukai T, Yamanaka R, Otani H, Matsumoto Y, Nakamura E, Takano M, Sada KE, Makino H.
    Regul Pept; 2010 Jun 08; 162(1-3):99-108. PubMed ID: 20346376
    [Abstract] [Full Text] [Related]

  • 14. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
    Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K.
    Biochem Biophys Res Commun; 2005 Mar 04; 328(1):91-7. PubMed ID: 15670755
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
    Itoh N, Kasai H, Ariyoshi W, Harada E, Yokota M, Nishihara T.
    J Periodontal Res; 2006 Aug 04; 41(4):273-9. PubMed ID: 16827720
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antioxidant alpha-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-kappaB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-kappaB ligand and tumor necrosis factor-alpha.
    Kim HJ, Chang EJ, Kim HM, Lee SB, Kim HD, Su Kim G, Kim HH.
    Free Radic Biol Med; 2006 May 01; 40(9):1483-93. PubMed ID: 16632109
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.